Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $29.02 USD
Change Today -1.59 / -5.19%
Volume 54.1K
HSKA On Other Exchanges
As of 3:39 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

heska corp (HSKA) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/15 - $35.72
52 Week Low
10/15/14 - $11.89
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HESKA CORP (HSKA)

Related News

No related news articles were found.

heska corp (HSKA) Related Businessweek News

No Related Businessweek News Found

heska corp (HSKA) Details

Heska Corporation develops, manufactures, markets, sells, and supports veterinary products for canine and feline companion animal health markets in the United States, Europe, and internationally. The company operates through two segments, Core Companion Animal Health; and Other Vaccines, and Pharmaceuticals and Products. The Core Companion Animal Health segment offers Element DC, DRI-CHEM 7000, and DRI-CHEM 4000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; Element POC blood gas and electrolyte analyzers; and IV pumps, as well as services and supports HESKA CBC-DIFF veterinary hematology system. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus Chewable Tablets for the prevention of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels. The Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and independent third-party distributors, as well as trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

301 Employees
Last Reported Date: 03/25/15
Founded in 1988

heska corp (HSKA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $260.3K
Co-Founder and Executive Chairman
Total Annual Compensation: $380.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $271.3K
President of Biologicals & Pharmaceuticals
Total Annual Compensation: $300.1K
Executive Vice President of Companion Animal ...
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2014.

heska corp (HSKA) Key Developments

Heska Corporation Announces Executive Changes

Heska Corporation named Mr. Jason Napolitano to the position of Chief Operating Officer, Effective on October 1, 2015. Mr. Napolitano will continue to serve in his existing capacities as Executive Vice President, Chief Financial Officer and Secretary of the company. Effective October 1, 2015, immediately following Dr. Grieve's resignation, the board appointed the then current Lead Director Sharon L. Riley as Chair of the board, eliminated the Lead Director position as the company now has an independent Chair who is neither an officer nor an employee of the company, and reduced the number of directors comprising the board to six directors from the previous level of seven directors.

Heska Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Heska Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue, net of $23,910,000 compared to $22,916,000 a year ago. Operating income was $1,829,000 compared to $917,000 a year ago. Income before income taxes was $1,792,000 compared to $924,000 a year ago. Net income attributable to the company was $1,197,000 or $0.17 per diluted share compared to $1,069,000 or $0.17 per diluted share a year ago. For the six months period, the company reported total revenue, net of $46,804,000 compared to $43,709,000 a year ago. Operating income was $2,850,000 compared to $816,000 a year ago. Income before income taxes was $2,676,000 compared to $807,000 a year ago. Net income attributable to the company was $1,795,000 or $0.26 per diluted share compared to $1,261,000 or $0.20 per diluted share a year ago.

Heska Corporation Announces Availability of Element i® Immunodiagnostic Analyzer

Heska Corporation announced the availability of the new Element i® Immunodiagnostic Analyzer. Element i performs immediate in-clinic testing and screening for key health concerns, including thyroid disorders, Cushing's disease and Addison's Disease. Heska's Element i is a compact bench top analyzer that delivers rapid immunoassay testing, including Total T4, Cortisol and the very first in-clinic TSH test available to North American veterinary hospital clients. The Heska Element i and its host of testing supplies will soon be available for order through Heska Corporation and Henry Schein Animal Health.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSKA:US $29.02 USD -1.59

HSKA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abaxis Inc $44.19 USD -1.50
Bio-Rad Laboratories Inc $134.84 USD -2.47
Hemagen Diagnostics Inc $0.03 USD 0.00
PetMed Express Inc $16.34 USD -0.21
Trinity Biotech PLC $11.99 USD +0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation HSKA Industry Range
Price/Earnings 66.4x
Price/Sales 2.1x
Price/Book 3.5x
Price/Cash Flow 63.7x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HESKA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at